... Skip to content
World IP Day 2026 — Recognized Innovator

Kyle Trudeau

  • Executive Director, Innovation Team
  • Sana Biotechnology, Inc.

Recognized as a named inventor and research leader at Sana Biotechnology, where his work spans in vivo gene delivery and cell engineering. His filings cover fusogen-based delivery systems, targeted lipid particles, and engineered cell compositions used in Sana’s cell therapy platform.

Certificate of Recognition

Top IP Innovator — Cell & Gene Therapy · 2026

Sana Patents (last 5 years)
0 +
First Filing
2019
USPTO Art Unit Focus
1633 / 1636
Role
Executive Director, Innovation Team
Presented by InspireIP

World IP Day Recognition Series · 2026

Sana Biotechnology patents, last 5 years
0 +
Filed in 2025 alone
0 +
Recognition category
0 Biotech
The Recognition

Engineering cells to become the medicine

Engineering cells to become the medicine

On World IP Day 2026, InspireIP recognizes Kyle Trudeau for his research leadership at Sana Biotechnology, a clinical-stage company developing engineered cells as medicines for diseases like Type 1 diabetes and B-cell cancers.

The recognition is based on Sana’s patent activity and public patent records where Kyle is named as an inventor. His filings cover targeted lipid particles, paramyxovirus fusogen systems, in vivo delivery of genetic payloads, hypoimmunogenic cell compositions, and repeated administration of viral vectors and lipid particles.

These patents sit close to Sana’s core work in gene delivery, cell engineering, and immune evasion.

Kyle holds a PhD from Boston University School of Medicine, where his doctoral research focused on mitochondrial biology, lysosomal function, and metabolic dysfunction. Kyle joined Sana in 2019 and now serves as Executive Director of the Innovation Team, leading research across the company’s in vivo cell engineering programs.

In Vivo Cell Engineering
Fusogen Delivery Systems
Hypoimmune Technology
Targeted Lipid Particles
Allogeneic Cell Therapy
Gene Therapy
Patent Footprint

A portfolio shaped around making the body its own bioreactor

2018–2019

Sana Biotechnology is founded in Seattle by former Juno Therapeutics executives. Kyle Trudeau joins in 2019 as a Senior Scientist. The company's first patent filings arrive, covering targeted lipid particles and fusosome delivery compositions.

2020–2021

The portfolio grows sharply, with 20 filings in 2020 and 34 in 2021. Sana goes public on NASDAQ in February 2021 with a $588 million IPO, one of the largest in biotech history for a preclinical company. The patent portfolio expands across both platforms, with filings covering Nipah virus G protein variants for targeted lentiviral delivery, methods for repeated vector administration, and hypoimmunogenic cell compositions.

2022–2023

There are 59 patents filed across two years, peaking at 45 filings in 2023. Sana advances its hypoimmune platform into clinical trials and initiates its in vivo CAR T program.

2024–2025

20 more patents across two years. Sana publishes groundbreaking results in the New England Journal of Medicine demonstrating that hypoimmune-modified pancreatic islet cells survive and produce insulin without immunosuppression in a patient with type 1 diabetes. The company focuses resources on SC451, its stem cell-derived islet cell therapy, and SG293, its in vivo CAR T candidate.

Cell & Gene Therapy Sector

A small-entity company filing like a category leader

Sana Biotechnology is classified by the USPTO as a Small Entity, yet its five-year filing volume sits well above what is typical for clinical-stage cell therapy companies of its size. 

Much of that activity is concentrated in the biotech and organic chemistry art units that protect engineered cell compositions, viral vector delivery systems, and methods for immune evasion in allogeneic transplantation.

Patents, last 5 years
+
Peak year (2023)
+ Filings
USPTO entity status
Small Entity
Art unit focus
1633 / 1636
"Leading an innovation program is harder than inventing on your own. It means choosing what to file, who to credit, and where to invest, over and over, for years. The leaders we recognize on World IP Day have done that consistently, and built something that compounds."

Sam Zellner

Founder, InspireIP · Inventor · Innovation Leader

About Sana Biotechnology, Inc.

Built in Seattle, engineering cells to cure disease

Founded in 2018 and headquartered in Seattle, Washington, Sana Biotechnology is a clinical-stage biopharmaceutical company developing engineered cells as medicines.

The company has two core platforms. Its Hypoimmune platform engineers cells to evade immune detection, supporting allogeneic transplantation without immunosuppression. Its Fusogen platform delivers genetic payloads directly to specific cells in the body, enabling in vivo cell engineering.

Sana’s advanced programs include UP421, a primary islet cell therapy for type 1 diabetes, and SC451, a stem cell-derived islet cell therapy with an IND filing expected in 2026. Its in vivo CAR T candidate, SG293, targets B-cell cancers and autoimmune diseases.

The company raised over $700 million in private financing and $588 million in its 2021 IPO, and trades on NASDAQ under the ticker SANA.

IP Day 2027

Know an IP innovator who deserves recognition?

Each year we recognize the inventors and IP leaders behind the portfolios that protect what their companies create. That includes founder-inventors whose contributions often go unmarked. Nominate someone for next year’s list.

Subscribe to Trust Center Updates

Subscribe to get notifications about important update to InspireIP's compliance journey.
By signing up for email notifications you agree to the privacy policy.

InspireIP has restricted access for 'System Acquisition and Development Lifecycle Policy'. We need your work email to validate OR request your access to this item.